Kineta Amends Merger Agreement with TuHURA Biosciences

The latest update is out from Kineta ( (KANT) ).

On May 5, 2025, Kineta, Inc. announced an amendment to its merger agreement with TuHURA Biosciences, Inc., initially set on December 11, 2024. This amendment revises the terms of the merger consideration, including the stock and cash considerations for Kineta’s shareholders. The merger involves a two-step process where Kineta will first merge with a TuHURA subsidiary, followed by a merger with another TuHURA subsidiary, resulting in Kineta’s shareholders receiving shares of TuHURA common stock and cash. The amendment also extends the merger’s end date to June 30, 2025, and requires TuHURA to secure a $20 million investment as a condition for the merger’s completion. This development is significant as it impacts the financial terms and timeline of the merger, potentially affecting the stakeholders involved.

Spark’s Take on KANT Stock

According to Spark, TipRanks’ AI Analyst, KANT is a Neutral.

Kineta faces financial challenges and lacks profitability, reflected in a low financial performance score. Technical analysis shows no strong trends, and valuation metrics are unappealing due to negative earnings. The recent merger announcement offers a positive outlook, but overall risks weigh heavily.

To see Spark’s full report on KANT stock, click here.

More about Kineta

Average Trading Volume: 14,142

Technical Sentiment Signal: Sell

Current Market Cap: $3.95M

For detailed information about KANT stock, go to TipRanks’ Stock Analysis page.